NCT05230940 is a Phase 2 clinical trial of TURKOVAC in COVID-19, sponsored by Health Institutes of Turkey.

Who is sponsoring NCT05230940?

NCT05230940 is sponsored by Health Institutes of Turkey.

What drugs are being tested in NCT05230940?

Interventions in NCT05230940: TURKOVAC, CoronaVac.

What condition does NCT05230940 study?

NCT05230940 studies COVID-19, Sars-CoV-2 Infection.

Is NCT05230940 still recruiting?

NCT05230940 is currently completed. Last updated 28 May 2024.

Last reviewed 2024-05-28 · How we verify

NCT05230940

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent

Completed Phase 2 Last updated 28 May 2024

What this trial tests

Phase 2 trial testing TURKOVAC in COVID-19 in 1 participant. Completed in 8 February 2024.

Timeline

18 February 2022

Primary endpoint
15 May 2023

8 February 2024

Quick facts

Lead sponsor	Health Institutes of Turkey
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	1
Start date	18 February 2022
Primary completion	15 May 2023
Estimated completion	8 February 2024
Sites	14 locations across Turkey (Türkiye)

Drugs / interventions tested

TURKOVAC — full drug profile →
CoronaVac — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Sars-CoV-2 Infection — all drugs for Sars-CoV-2 Infection →

Sponsor

Health Institutes of Turkey

Who can join

Adults 12 to 18, any sex, with COVID-19 or Sars-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multi-center, randomized, national, observer-blinded, active-controlled phase IIB clinical trial to determine the efficacy, immunogenicity, and safety of two-doses of inactive COVID-19 vaccine (TURKOVAC) vaccine versus the two-doses CoronaVac (Sinovac) vaccine in healthy adolescents aged 12-18 years.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials.
Tian F, Yang R, Chen Z. · · 2022 · cited 47× · PMID 35705969 · DOI 10.1002/jmv.27940

Verify or expand the search:

Other trials of TURKOVAC

Trials testing the same drug.

NCT06997653 — Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Pregnant Women · Phase 2 · withdrawn

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Health Institutes of Turkey trials

Trials by the same sponsor.

NCT07502118 — NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) · Phase 2, PHASE3 · recruiting
NCT06997653 — Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Pregnant Women · Phase 2 · withdrawn
NCT05863429 — Observational National Vaccine Study · completed
NCT05210179 — Phase 2b Booster Vaccination (TURKOVAC) Against COVID-19 · Phase 2 · completed
NCT05077176 — Phase 3 Booster Vaccination Against COVID-19 · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05230940 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Health Institutes of Turkey
Last refreshed: 28 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05230940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing